

## Details of Q4 FY22 Investor Webinar

**Microba Life Sciences Limited** (ASX: MAP) ("Microba" or the "Company") will release its Q4 FY22 Quarterly Activities Report & Appendix 4C on Wednesday, 20 July 2022 pre-market.

An investor webinar will be held to discuss the Q4 FY22 results. Please find the details below:

**Presenting:** Microba CEO, Dr Luke Reid

**Time:** 9:15 am AEST on Thursday, 21 July 2022

To register for the session and for more information on the conference click below. Investors can submit questions prior to the webinar to [simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au) or do so via the Q&A functions on Zoom.

[https://us02web.zoom.us/webinar/register/WN\\_eecvig3sRLKyRhEwLPwE3Q](https://us02web.zoom.us/webinar/register/WN_eecvig3sRLKyRhEwLPwE3Q)

*This announcement has been authorised for release by the Chairman and Chief Executive Officer.*

For further information, please contact:

**Dr Luke Reid**

Chief Executive Officer

E: [Luke.Reid@microba.com](mailto:Luke.Reid@microba.com)

**Simon Hinsley**

Investor / Media Relations

E: [simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au)

T: +61 401 809 653

### About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

**For more information visit: [www.microba.com](http://www.microba.com)**

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.